Need professional-grade analysis? Visit stockanalysis.com
$1.35B
N/A
N/A
N/A
Novocure Ltd (NVCR) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at $12.23, down 4.68% from the previous close.
Over the past year, NVCR has traded between a low of $10.03 and a high of $19.40. The stock has lost 25.9% over this period. It is currently 37.0% below its 52-week high.
Novocure Ltd has a market capitalization of $1.35B.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Side-by-side comparison against top Healthcare peers.